What is Acquired Resistance and How Does it Occur?

Gregory J. Riely, MD, PhD, GRACE Faculty

Acquired Resistance Forum Video #1: Dr. Gregory J. Riely of Memorial Sloan Kettering Cancer Center opened the Acquired Resistance in Lung Cancer Patient Forum with a basic introduction of how ALK, ROS1 and EGFR lung cancers become resistant to treatment.

Related Content:

Tagrisso for acquired resistance to Tarceva

EGFR Mutations and Acquired Resistance After Responding

Heterogeneity in Population of NSCLC Patients with Acquired Resistance to EGFR Inhibitors: T790M is Key Predictor

Webinar by Dr. Lecia Sequist on Acquired Resistance to Oral EGFR Inhibitors in Advanced NSCLC

New Hope for EGFR Mutant NSCLC with Acquired Resistance to Tarceva (including T790M!)

HSP 90 Inhibitors: Another Rational Choice for Patients with Acquired Resistance to EGFR Inhibitors

Challenging Cases in Lung Cancer: Acquired Resistance to an EGFR Inhibitor in a Patient with Advanced NSCLC and EGFR Mutation

Early Data on Acquired Resistance to Targeted Therapies: Start Local Therapy, Continue the Targeted Therapy?

Should We Continue the EGFR Inhibitor When We Start Chemo for Acquired Resistance?